{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T13:19:27Z","timestamp":1772889567352,"version":"3.50.1"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Globus, Medtronic, and Cerapedics, and royalties from Royal Biologics"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>These 2 prospective studies investigated whether the injection site influences pain and local reactions with romosozumab treatment for osteoporosis. In Study 1, 169 patients were randomly assigned to receive monthly romosozumab 210\u00a0mg (2 vials) injections for 12\u00a0mo in either the abdomen (Abd group) or upper arm (Arm group). In Study 2, 55 patients received 105\u00a0mg (1 vial) injections in both sites to directly compare pain at each location. Pain was evaluated using a Visual Analog Scale (VAS, mm), and secondary outcomes included BMD, bone turnover markers (BTMs) (total P1NP and TRACP-5b), and injection site reactions (ISRs). In the randomized trial, 70 of 85 patients (82.4%) in the Abd group and 69 of 84 (82.1%) in the Arm group completed the study. The Arm group reported significantly greater pain than the Abd group, starting after the fifth injection (mean difference, 6.8\u00a0mm [95% CI, 0.7-12.8]; p\u2009=\u2009.029) and continuing through the 12th injection (9.5\u00a0mm [95% CI, 2.9-16.1]; p\u2009=\u2009.005). Although crude ISR rates were similar (Abd, 26.2% vs Arm, 35.8%; p\u2009=\u2009.24), multivariable analysis showed a higher ISR incidence in the Arm group (incidence rate ratio: 1.73 [95% CI, 1.01-2.95]; p\u2009=\u2009.045). In Study 2, pain was consistently greater at the upper arm, beginning with the first injection (mean difference, 5.2\u00a0mm [95% CI, 1.7-8.7]; p\u2009=\u2009.004) and continuing through the 12th (8.1\u00a0mm [95% CI, 4.2-11.9]; p\u2009&amp;lt;\u2009.001). BMD and BTMs did not differ between sites. In conclusion, upper arm injections were associated with greater pain and higher ISR incidence without affecting bone metabolism. Selecting an injection site based on comfort may improve patient experience during romosozumab therapy.<\/jats:p>","DOI":"10.1093\/jbmrpl\/ziag022","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T12:47:11Z","timestamp":1770814031000},"source":"Crossref","is-referenced-by-count":0,"title":["Upper arm administration is associated with higher injection site pain with romosozumab: a randomized controlled trial and a self-controlled study"],"prefix":"10.1093","volume":"10","author":[{"given":"Soji","family":"Tani","sequence":"first","affiliation":[{"name":"Department of Orthopaedic Surgery, Showa Medical University , Tokyo, 142-8666 ,","place":["Japan"]},{"name":"Department of Orthopaedic Surgery, Yamanashi Red Cross Hospital , Yamanashi, 401-0301 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Asada","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Hospital for Special Surgery , New York, NY 10021 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiro","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Showa Medical University , Tokyo, 142-8666 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Passias","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Duke University , Durham, NC 27710 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koki","family":"Tsuchiya","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Showa Medical University , Tokyo, 142-8666 ,","place":["Japan"]},{"name":"Department of Orthopaedic Surgery, Yamanashi Red Cross Hospital , Yamanashi, 401-0301 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahoko","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Duke University , Durham, NC 27710 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Richardson","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Duke University , Durham, NC 27710 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshifumi","family":"Kudo","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Showa Medical University , Tokyo, 142-8666 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Alman","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Duke University , Durham, NC 27710 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3689-5662","authenticated-orcid":false,"given":"Koji","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Showa Medical University , Tokyo, 142-8666 ,","place":["Japan"]},{"name":"Department of Orthopaedic Surgery, Duke University , Durham, NC 27710 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"issue":"12","key":"2026030612015668500_ref1","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","article-title":"An estimate of the worldwide prevalence and disability associated with osteoporotic fractures","volume":"17","author":"Johnell","year":"2006","journal-title":"Osteoporos Int"},{"issue":"1","key":"2026030612015668500_ref2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s00223-012-9666-6","article-title":"Assessing the impact of osteoporosis on the burden of hip fractures","volume":"92","author":"Oden","year":"2013","journal-title":"Calcif Tissue Int"},{"issue":"5","key":"2026030612015668500_ref3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/pl00004148","article-title":"World-wide projections for hip fracture","volume":"7","author":"Gullberg","year":"1997","journal-title":"Osteoporos Int"},{"issue":"15","key":"2026030612015668500_ref4","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"issue":"16","key":"2026030612015668500_ref5","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"2026030612015668500_ref6","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1007\/s12325-019-01101-6","article-title":"Subcutaneous injection of drugs: literature review of factors influencing pain sensation at the injection site","volume":"36","author":"Usach","year":"2019","journal-title":"Adv Ther"},{"issue":"1","key":"2026030612015668500_ref7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.gastrohep.2019.06.008","article-title":"Impact of pain associated with the subcutaneous administration of adalimumab","volume":"43","author":"Gely","year":"2020","journal-title":"Gastroenterol Hepatol"},{"issue":"4","key":"2026030612015668500_ref8","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/1756-185x.13803","article-title":"Adherence to subcutaneous anti-TNF\u03b1 agents in patients with rheumatoid arthritis is largely influenced by pain and skin sensations at the injection site","volume":"23","author":"Salaffi","year":"2020","journal-title":"Int J Rheum Dis"},{"issue":"8","key":"2026030612015668500_ref9","doi-asserted-by":"publisher","first-page":"e069625","DOI":"10.1136\/bmjopen-2022-069625","article-title":"Pain related to intravitreal injections for age-related macular degeneration: a qualitative study of the perspectives of patients and practitioners","volume":"13","author":"Yiallouridou","year":"2023","journal-title":"BMJ Open"},{"issue":"3","key":"2026030612015668500_ref10","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00774-013-0447-8","article-title":"Diagnostic criteria for primary osteoporosis: year 2012 revision","volume":"31","author":"Soen","year":"2013","journal-title":"J Bone Miner Metab"},{"issue":"5","key":"2026030612015668500_ref11","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1507\/endocrj.EJ23-0040","article-title":"Multidisciplinary approach to management of osteoporosis with osteoporosis liaison service (OLS)","volume":"70","author":"Suzuki","year":"2023","journal-title":"Endocr J"},{"key":"2026030612015668500_ref12","article-title":"Conservative sample size determination for repeated measures analysis of covariance","volume":"1","author":"Morgan","year":"2013","journal-title":"Ann Biom Biostat"},{"key":"2026030612015668500_ref13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12874-016-0144-0","article-title":"Single time point comparisons in longitudinal randomized controlled trials: power and bias in the presence of missing data","volume":"16","author":"Ashbeck","year":"2016","journal-title":"BMC Med Res Methodol"},{"key":"2026030612015668500_ref14","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.RVW.N.00009","article-title":"An introduction to the linear mixed model for orthopaedic research","volume":"2","author":"Kwon","year":"2014","journal-title":"JBJS Rev"},{"issue":"1","key":"2026030612015668500_ref15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/art.23253","article-title":"Missing data in randomized controlled trials of rheumatoid arthritis with radiographic outcomes: a simulation study","volume":"59","author":"Baron","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2026030612015668500_ref16","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/1471-2288-13-100","article-title":"Selecting a sample size for studies with repeated measures","volume":"13","author":"Guo","year":"2013","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"2026030612015668500_ref17","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jvn.2018.06.003","article-title":"Comparison of abdominal and arm areas in patients receiving subcutaneous heparin in terms of development of pain, hematoma, and ecchymosis","volume":"36","author":"Cengiz","year":"2018","journal-title":"J Vasc Nurs"},{"issue":"4","key":"2026030612015668500_ref18","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1177\/12034754231188444","article-title":"A systematic review and meta-analysis of injection site reactions in randomized-controlled trials of biologic injections","volume":"27","author":"Kim","year":"2023","journal-title":"J Cutan Med Surg"},{"issue":"7-8","key":"2026030612015668500_ref19","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1177\/106002809603000703","article-title":"Pain assessment of subcutaneous injections","volume":"30","author":"J\u00f8rgensen","year":"1996","journal-title":"Ann Pharmacother"},{"issue":"3","key":"2026030612015668500_ref20","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.3390\/ijms26031289","article-title":"The human superficial fascia: a narrative review","volume":"26","author":"Fede","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2026030612015668500_ref21","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1185\/03007995.2010.481203","article-title":"Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations","volume":"26","author":"Gibney","year":"2010","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"2026030612015668500_ref22","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/s0272-6386(12)80928-0","article-title":"Identification of the component part in an epoetin alfa preparation that causes pain after subcutaneous injection","volume":"22","author":"Frenken","year":"1993","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"2026030612015668500_ref23","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/j.1742-7843.2006.pto_271.x","article-title":"Pain perception after subcutaneous injections of media containing different buffers","volume":"98","author":"Laursen","year":"2006","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"10","key":"2026030612015668500_ref24","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1111\/dom.12304","article-title":"Impact of injection speed and volume on perceived pain during subcutaneous injections into the abdomen and thigh: a single-centre, randomized controlled trial","volume":"16","author":"Heise","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"2026030612015668500_ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2021.101068","article-title":"Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: a prospective cohort study","volume":"14","author":"Kobayakawa","year":"2021","journal-title":"Bone Rep"},{"issue":"3","key":"2026030612015668500_ref26","doi-asserted-by":"publisher","first-page":"e1356","DOI":"10.1002\/jsp2.1356","article-title":"The potential effect of romosozumab on perioperative management for instrumentation surgery","volume":"7","author":"Ishikawa","year":"2024","journal-title":"JOR Spine"},{"issue":"2","key":"2026030612015668500_ref27","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/cpt.1193","article-title":"Adverse events associated with PCSK9 inhibitors: a real-world experience","volume":"105","author":"Gurgoze","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"2026030612015668500_ref28","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/jbmr.3622","article-title":"One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study","volume":"34","author":"Lewiecki","year":"2019","journal-title":"J Bone Miner Res"}],"container-title":["JBMR Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmrplus\/advance-article-pdf\/doi\/10.1093\/jbmrpl\/ziag022\/66901563\/ziag022.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/10\/4\/ziag022\/66901563\/ziag022.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/10\/4\/ziag022\/66901563\/ziag022.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T17:02:02Z","timestamp":1772816522000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article\/doi\/10.1093\/jbmrpl\/ziag022\/8483867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,2,28]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmrpl\/ziag022","relation":{},"ISSN":["2473-4039"],"issn-type":[{"value":"2473-4039","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,2,14]]},"article-number":"ziag022"}}